FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Dexcel gets right to sell copycat Prilosec

The fight is over. Over-the-counter drug distributor Perrigo said its partner Dexcel Pharma Technologies has settled patent litigation with AstraZeneca over the heartburn med Prilosec OTC. The settlement deal will allow Dexcel to sell a store-brand version of the drug as soon as it gets FDA's approval.

The patent fight has been going on since May 2006, when AZ sued to block Dexcel's new drug application. Now, AZ has waived its patent claims on Dexcel's product. Perrigo, which will be the exclusive distributor for the drug, expecting sales of $150 million to $200 million. Overall, Prilosec OTC sells at the rate of $750 million annually.

- see this release from Perrigo (.pdf)
- read the report from the Houston Chronicle

Related Articles:
Canada questions safety of Nexium, Prilosec. Report
FDA to review Nexium, Prilosec. Report

More stories about FDA approval   Astrazeneca   heartburn  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 1 + 3?
To combat spam, please solve the math question above.